Adagene Inc. ADAG
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $7.67M, +7332.8% YoY · Filed Apr 1, 2026
Adagene Inc. (ADAG) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $7.7 million and a net loss of $17.6 million. Free cash flow was -$15.7 million. As of Dec 31, 2025 it held $74.5 million in cash and investments and $6.3 million in total debt.
Revenue
$7.67M
+7332.8% vs prior year
Net income
$-17.61M
+47.3% vs prior year
Operating cash flow
$-15.66M
+47.3% vs prior year
Free cash flow
$-15.67M
+47.3% vs prior year
EPS
$-0.30
+49.2% vs prior year
Dividend per share
None
Shares outstanding
59.23M
+0.6% vs prior year
Net cash
$68.26M
FY 2025
Operating margin
-279.5%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ADAG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Jiangsu, China
- SEC filer status
- Accelerated filer, Emerging growth company
- SEC CIK
- 1818838
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $7.7M | $103,204 | $18.1M | $9.3M | $10.2M |
| Operating income | -$21.4M | -$36.0M | -$23.7M | -$83.9M | -$72.4M |
| Net income | -$17.6M | -$33.4M | -$18.9M | -$80.0M | -$73.2M |
| Diluted EPS | -$0.30 | -$0.59 | -$0.35 | -$1.48 | -$1.46 |
| Operating cash flow | -$15.7M | -$29.7M | -$28.5M | -$48.6M | -$43.4M |
| Free cash flow | -$15.7M | -$29.7M | -$28.5M | -$49.3M | -$45.9M |
| Total assets | $78.3M | $89.3M | $115.7M | $152.4M | $189.5M |
| Total liabilities | $26.4M | $38.7M | $45.2M | $69.3M | $33.0M |
| Stockholders' equity | $35.3M | $50.5M | $70.6M | $83.1M | $156.6M |
| Cash and investments | $74.5M | $85.2M | $109.9M | $143.8M | $174.4M |
| Total debt | $6.3M | $18.5M | $22.3M | $28.0M | $7.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Sep 25, 2026 | Sep 25, 2026 |
| 6-K | Current report (foreign issuer) | Sep 22, 2026 | Sep 22, 2026 |
| 6-K | Current report (foreign issuer) | Sep 10, 2026 | Sep 10, 2026 |
| 6-K | Current report (foreign issuer) | Sep 9, 2026 | Sep 9, 2026 |
| 6-K | Current report (foreign issuer) | Aug 12, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jul 6, 2026 | Jul 6, 2026 |
All 191 Adagene Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.